Table of contents

• Trial overview
• Who is being studied
• Study design and phase
• What the trial measures
• Trial status and size
• Patient-focused summary

Trial overview

This clinical research is about antithrombotic treatment, which means treatment aimed at preventing blood clots.^[1] The study title says it is an APAC antithrombotic treatment study for limb-threatening impairment of blood flow, also called the HEALING-study.^[1]

The trial compares APAC with sodium chloride and with Heparin LEO 5000 IU/ml injektioneste, liuos, all given by intravenous use in the study plan.^[1] The source data do not give more detail about the substance UNFRACTIONATED HEPARIN, PORCINE, CONJUGATED WITH HUMAN SERUM ALBUMIN itself, so this article focuses only on the trial information provided.^[1]

Who is being studied

The trial targets people with peripheral arterial occlusive disease (PAOD) and chronic limb-threatening ischemia (CLTI).^[1] PAOD means the arteries in the arms or legs are narrowed or blocked, while CLTI means a severe form of poor blood flow that can threaten the limb.^[1]

The brief summary also says the study is in patients undergoing endovascular revascularization, which is a procedure done inside the blood vessels to improve blood flow.^[1] This tells us the study population is not general healthy volunteers, but patients with serious circulation problems who need a vessel procedure.^[1]

Study design and phase

This is an interventional study, meaning the researchers give a treatment and then observe what happens.^[1] It is listed as Phase 2, which usually means the study is looking more closely at safety and early signs of benefit in a smaller group of patients.^[1]

The brief summary divides the work into Part A and Part B.^[1] Part A is designed to evaluate the safety and tolerability of intravenous APAC for a single infusion and weekly dosing, while Part B is meant to establish the safety of selected doses and dosing frequency for periprocedural intra-arterial and weekly intravenous APAC in patients having endovascular revascularization.^[1]

What the trial measures

The main endpoint is the occurrence and severity of treatment-emergent adverse events (TEAEs), which are health problems that appear or become worse after treatment starts.^[1] In Part A, TEAEs are measured from baseline to Day 29 and Day 90 after the first dose of APAC, depending on the part of the study.^[1]

The study also records physical examination findings, vital signs, clinical laboratory data, and bleeding events measured with the ISTH bleeding score, a standard way to describe bleeding in clinical research.^[1] In Part B, the trial also tracks surgical adverse events using the Clavien-Dindo classification, which is a system for grading how serious surgical complications are.^[1]

These outcomes show that the study is mainly focused on safety, tolerability, and bleeding risk rather than on long-term effectiveness outcomes.^[1]

Trial status and size

The trial status is Authorised.^[1] The planned enrollment is 42 participants, which means the study is relatively small.^[1]

Small Phase 2 studies like this are often used to gather early information before larger studies are done.^[1] In this case, the source data show a focused safety study in a specific high-risk patient group.^[1]

Patient-focused summary

For patients, the key point is that this research is looking at people with serious limb blood flow problems who may need a vessel-opening procedure.^[1] The study is testing how safe and tolerable the treatment plan is, and it watches closely for bleeding and other side effects.^[1] The trial does not describe cure outcomes in the source data; instead, it mainly checks whether the treatment can be given safely in this setting.^[1]